skip to Main Content

Publications 2019

Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington’s disease.

Vezzoli E, Caron I, Talpo F, Besusso D, Conforti P, Battaglia E, Sogne E, Falqui A, Petricca L, Verani M, Martufi P, Caricasole A, Bresciani A, Cecchetti O, Rivetti di Val Cervo P, Sancini G, Riess O, Nguyen H, Seipold L, Saftig P, Biella G, Cattaneo E, Zuccato C.
J Clin Invest. 2019 May 6;130.

Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery.

Borbély A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N.
Pharmaceutics 2019, 11(4), 151.

A novel method using nuclear magnetic resonance for plasma proteinbinding assessment in drug discovery programs.

Gallo M, Matteucci S, Alaimo N, Pitti E, Orsale MV, Summa V, Cicero DO, Monteagudo E.
Journal of Pharmaceutical and Biomedical Analysis 167 (2019) 21–29.

Back To Top